Capsule endoscopy is a non-invasive approach that aids healthcare providers in diagnosing conditions such as gastrointestinal bleeding, Barrett’s oesophagus, inflammatory bowel disease (IBD), and other gastrointestinal disorders. Driven by growing demand for minimally invasive procedures, the capsule endoscopy market in North America is set to experience steady growth, registering a compound annual growth rate (CAGR) of 6.2 per cent from 2024 to 2034, forecasts GlobalData.
According to GlobalData, within the North American region, Canada is anticipated to see the strongest growth at a 7.0 per cent CAGR, followed by Mexico with 6.2 per cent, and the US at 6.1 per cent.
Thomas Fleming, Medical Analyst at GlobalData, comments, “Market growth in North America, with the US making up the largest portion of the market, is largely driven by an increasing population, a rising incidence of gastrointestinal diseases, and a growing preference among patients and providers for minimally invasive procedures. Technological advancements aimed at enhancing imaging quality and control capabilities of these capsule devices are further accelerating market adoption.”
Capsule endoscopy involves the utilisation of small medical devices, typically weighing between 1.9 grams and 4.0 grams. These capsules are equipped with a battery, light source, camera, and transmitter. Once ingested by the patient, the capsule travels through the digestive tract, transmitting detailed images from the oesophagus, stomach, and small bowel to an external receiver.
Fleming concludes, “The market is also witnessing expansion as new applications for capsule endoscopy emerge, replacing traditional endoscopic procedures. Currently, Medtronic holds a dominant position within this market in North America, capturing a substantial 89.4 per cent market share. Continued innovation and expanded indications for capsule endoscopy are expected to sustain robust market growth throughout the forecast period.”